Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Another market introduction for Merck's short-acting antiplatelet agent Aggrastat

Sep. 9, 1999

ME-3230, an orally active prodrug of a potent gpIIb/IIIa antagonist

Aug. 31, 1999

Oral bioavailability of thrombin inhibitor S-31922 shows reduced variability in the presence of food

Aug. 30, 1999

Servier researchers present S-31214, a potent and selective thrombin inhibitor, at ACS

Aug. 30, 1999

Emisphere Technologies foresees initiation of phase III testing for oral heparin

Aug. 30, 1999

SR-123781A, a novel heparin mimetic with advantages over standard heparin

Aug. 27, 1999

Double prodrug UR-3216, a potent, long-lasting and orally active gpIIb/IIIa antagonist

Aug. 27, 1999

Corvas enters rNAPc2 manufacturing agreement in anticipation of phase III trials

Aug. 27, 1999

Roche Canada obtains licensing and marketing rights to TNK-tPA

Aug. 26, 1999

ACS presentation for new factor Xa inhibitor from Rhone-Poulenc Rorer

Aug. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...